2015

  1. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma, Damber JE. Eur Urol. Dec 2015 Sammanfattning, Fulltext
  2. Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort, Eur Urol. Dec 17, 2015 Sammanfattning, Fulltext
  3. Lindhagen L, Van Hemelrijck M, Robinson D, Stattin P, Garmo H. How to model temporal changes in comorbidity for cancer patients using prospective cohort data, BMC Med Inform Decis Mak. Nov 18, 2015 Sammanfattning, Fulltext
  4. Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base-a refined prostate cancer trajectory, Int J Epidemiol, Dec 11, 2015 Sammanfattning, Fulltext
  5. Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P. Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study, Int J Cancer. Dec 14, 2015 Sammanfattning, Fulltext
  6. O’Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, Van Hemelrijck M. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation, BJU Int. Oct 24, 2015 Sammanfattning
  7. Robinson D, Garmo H, Stattin P, Michaëlsson K. Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study, PLoS One, Oct 15, 2015 Sammanfattning
  8. Jan M, Bonn SE, Sjölander A, Wiklund F, Stattin P, Holmberg E, Grönberg H, Bälter K. The roles of stress and social support in prostate cancer mortality. Scand J Urol, Sep 7, 2015 Sammanfattning
  9. Stattin P, Sandin F, Sandbäck T, Damber JE, Franck Lissbrant I, Robinson D, Bratt O, Lambe M, Dashboard report on performance on select quality indicators to cancer care providers, Scand J Urol, Jul 10, 2015 Sammanfattning
  10. Stattin P, Robinson D, Lambe M, Re: Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, et al. Prostate Cancer Registries: Current Status and Future Directions, Eur Urol, Jul 13, 2015 Sammanfattning, Fulltext
  11. Loeb S, Schlomm T, Stattin P, Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma, Eur Urol, Jul 31, 2015 Sammanfattning
  12. Stattin K, Sandin F, Bratt O, Lambe M, The risk of distant metastases and cancer-specific survival in men with serum prostate-specific antigen values above 100 ng/ml, J Urol, Jul 17, 2015 Sammanfattning
  13. Robinson D, Garmo H, Holmberg L, Stattin P, 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer, Cancer Causes Control, Jun 25, 2015 Sammanfattning, fulltext
  14. Markt SC, Grotta A, Nyren O, Adami HO, Mucci LA, Valdimarsdottir UA, Stattin P, Bellocco R, Lagerros YT, Insufficient Sleep and Risk of Prostate Cancer in a Large Swedish Cohort, Sleep, Jan 18, 2015 Sammanfattning
  15. Stacy Loeb, Yasin Folkvaljon, Mats Lambe, David Robinson, Hans Garmo, Christian Ingvar, Pӓr Stattin, Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma, JAMA. Jun 23, 2015 Sammanfattning
  16. Carlsson S, Drevin L, Loeb S, Widmark A, Franck Lissbrant I, Robinson D, Johansson E, Stattin P, Fransson P, Population-based study of long-term functional outcomes after prostate cancer treatmentm, BJU Int. May 8, 2015 Sammanfattning
  17. Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, Franck Lissbrant I, Makarov D, Loeb S, Stattin P, Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer, Eur Urol. Mar 2, 2015 Sammanfattning, fulltext
  18. O’Farrel S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M, Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer, J Clin Oncol, Mars 2, 2015, Sammanfattning
  19. Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, Petterson K, Scardino PT, Hallmans G, Lilja H, Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study, Eur Urol, Feb 11, 2015, Fulltext
  20. Bonn, SE, Sjölander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, Grönberg H, Bälter K, Physical Activity and Survival among Men Diagnosed with Prostate Cancer, Cancer Epidemiol Biomarkers Prev Jan 24, 2015 Sammanfattning
  21. Van Hemelrijck M, Folvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H, Stattin P, Causes of death in men with localised prostate cancer: a nationwide, population-based study, BJU Int, Jan 21, 2015, Sammanfattning
  22. Grott A, Bottai M, Adami HO, Adams SA, Akre O, Blair SN, Mariosa D, Nyrén O, Ye W, Stattin P, Bellocco R, Lagerros YT, Physical activity and body mass index as predictors of prostate cancer risk, World J Urol, Jan 4, 2015. Sammanfattning